MedAvail Holdings, Inc.

NasdaqCM:MDVL Rapport sur les actions

Capitalisation boursière : US$2.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MedAvail Holdings Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de MedAvail Holdings.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Consumer Retailing croissance des bénéfices9.2%
Taux de croissance des recettesn/a
Rendement futur des capitaux propresn/a
Couverture par les analystes

None

Dernière mise à journ/a

Mises à jour récentes de la croissance future

Recent updates

Article d’analyse • Aug 17

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

MedAvail Holdings, Inc. ( NASDAQ:MDVL ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Aug 02

MedAvail Holdings: More Stock Dilution Seems Inevitable And I'm Bearish

MedAvail is a prescription drug-dispensing kiosks startup whose revenues are growing by over 100% year-on-year at the moment. However, the gross margin is barely positive and the operating loss expanded to $12.8 million in Q1 2022. Cash used in operational activities rose to $13.3 million in Q1 2022 and I think that the company will need another capital increase around the end of the year. However, short selling seems dangerous at the moment as the short borrow fee rate is almost 80%. Introduction I like writing about under covered stocks on SA, and today I'm taking a look at MedAvail Holdings (MDVL). It's a company focused on pharmacy automation kiosks and the growth of its business looks compelling. However, the operating expenses are high and the company is set to run low on cash again soon. I think that another stock dilution seems inevitable in the near future. Overall, I don't think that the business is worth much in its current state and I'm bearish. Let's review. Overview of the business and financials MedAvail is a pharmacy technology and services company whose main product is a MedCenter. This is a pharmacist controlled, customer-interactive, prescription dispensing system that looks somewhat like an ATM on the outside. MedAvail It's an interesting concept but there are several competitors with a similar business, including Omnicell (NASDAQ: OMCL) Dispension Industries, Pharmaself24. What MedAvail is offering doesn't seem to be unique. The company also operates full-service retail pharmacies under the SpotRx brand that use its automated pharmacy technology. MedAvail has bet on a hub and spoke model and it currently has operations in the states of Arizona, California, Michigan, and Florida. It plans to set foot in Texas and Illinois in the near future. MedAvail has partnered with several large brands, including IMA Medical Group, CareMore Health, Cigna (NYSE: CI), and Cano Health. MedAvail The dispensing units usually ramp up to $1 million in annual revenues by their second year. As of December 2021, MedAvail had a total of 13 dispensing units that were operating for over 18 months, and it plans to set up about 25-30 dispensing units in 2022. For the graphs below, note that net cumulative deployments exclude decommissioned clinics, pilot and demo sites. MedAvail MedAvail In Q1 2022, retail pharmacy and hardware revenues increased by 126.3% year-on-year thanks to a $5.4 million increase from volume growth in prescription revenue at existing sites as well as new sites in Florida and Michigan. Unfortunately, there don't appear to be significant economies of scale as the total cost of products sold and services soared by 132.3% to $8.61 million. In addition, operating expenses rose by 33.1% which led to a widening of the operating loss of MedAvail to $12.8 million in Q1 2022. MedAvail Looking at the future, the targeted milestones listed in MedAvail's latest corporate presentation include increasing the network of dispensing MedCenters to more than 100 in existing markets. I don't think this should be hard to achieve considering there were already 88 dispensing units in operation as of March 2022, up from 68 units in December 2021. The company also aims to reduce its quarterly cash burn by 20% by improving its gross margin and achieving greater hub pharmacy utilization. It also highlighted a procurement strategy for sourcing pharmaceuticals at optimal cost to drive utilization and the appropriate mix of medications. However, I don't see a path to profitability anytime soon considering the gross margin hasn't seen much improvement over the past few quarters and that the operating loss has increased by over 37% in just a year. In my view, this is a major issue as it has led to an increase of net cash used in operating activities to $13.3 million in Q1 2022, compared to $9.8 million a year earlier. As a result, MedAvail closed March with cash and cash equivalents of only $5.27 million. The company then raised $40 million through the issuance of 37.6 million shares at $1.0625 apiece in April 2022. Yet, I think that another large private placement is likely to take place around the end of 2022 due to the increase of cash used in operating activities. I think that more stock dilution seems inevitable at the moment. Turning our attention to the balance sheet, we can see that MedAvail has an asset-light business model and cash, receivables, and inventories accounted for almost half of the $27.7 million in total assets at the end of Q1 2022. I find it concerning that the accumulated deficit has surpassed $200 million. MedAvail Overall, I expect MedAvail to continue growing its revenues at a rapid pace and I think the annual run rate could surpass $50 million by the end of 2022. However, the gross margin is barely positive and when you add operating expenses, the picture isn't pretty. And with net cash used in operations growing rapidly, I think that another large capital increase is likely in a few months. I'm bearish but I don't think that this is a good time to be short selling MedAvail. According to data from Fintel, there are 250,000 shares available for borrowing as of the time of writing but the short borrow fee rate is 79.39%. And if you want to rely on put options instead, the lowest available strike price at the moment is $2.50.
Article d’analyse • Aug 17

Some Analysts Just Cut Their MedAvail Holdings, Inc (NASDAQ:MDVL) Estimates

The latest analyst coverage could presage a bad day for MedAvail Holdings, Inc ( NASDAQ:MDVL ), with the analysts...
Article d’analyse • May 24

Calculating The Intrinsic Value Of MedAvail Holdings, Inc (NASDAQ:MDVL)

Does the May share price for MedAvail Holdings, Inc ( NASDAQ:MDVL ) reflect what it's really worth? Today, we will...
Article d’analyse • Feb 20

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

In this article we are going to estimate the intrinsic value of MedAvail Holdings, Inc ( NASDAQ:MDVL ) by taking the...

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme MedAvail Holdings n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:MDVL - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
6/30/202343-54-32-32N/A
3/31/202343-55-41-40N/A
12/31/202243-48-50-48N/A
9/30/202220-36-55-52N/A
6/30/202214-35-55-52N/A
3/31/202218-40-49-46N/A
12/31/202122-44-46-43N/A
9/30/202118-43-44-41N/A
6/30/202119-34-37-35N/A
3/31/202117-31-34-33N/A
12/31/202014-27-29-29N/A
9/30/202012-21-21-20N/A
6/30/20206-24-20-20N/A
3/31/20204-22-21-21N/A
12/31/20194-22-20-20N/A
12/31/20185-17-13-12N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de MDVL est supérieure au taux d'épargne ( 2.2% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de MDVL devraient croître plus rapidement que le marché US

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de MDVL devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de MDVL devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de MDVL devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MDVL devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2024/02/03 14:47
Cours de l'action en fin de journée2024/02/02 00:00
Les revenus2023/06/30
Revenus annuels2022/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

MedAvail Holdings, Inc. est couverte par 2 analystes. de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Brooks O'NeilLake Street Capital Markets, LLC
Charles RhyeeTD Cowen